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Abstract
Background: Neurosarcoidosis is a rare manifestation of 
hepatitis C virus (HCV) infection, mainly in patients exposed 
to interferon-based therapies. Although we are living in a 
new era of HCV treatment, there is still little data concerning 
the treatment of extrahepatic complications of the disease 
with direct antiviral agents, especially rare ones such as neu-
rosarcoidosis. Summary: We present a rare case of central 
nervous system vasculitic lesions in the context of chronic 
HCV infection associated with mixed cryoglobulinemia, ele-
vated angiotensin-converting enzyme (ACE) levels, and doc-
umentation of viral RNA in the cerebrospinal fluid in a treat-
ment-naïve chronic HCV patient. Successful treatment with 
an interferon-free regimen improved all clinical manifesta-
tions, reduced the levels of serum ACE, and reduced the 
cryoglobulin levels to undetectable. Messages: Neurosar-
coidosis and cryoglobulinemia are rare but well-recognized 
complications of HCV infection, even in treatment-naïve pa-
tients. Direct antiviral agents can be useful in the manage-
ment of this condition.
© 2018 Sociedade Portuguesa de Gastrenterologia 
Published by S. Karger AG, Basel
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Resumo
Introdução: A neurossarcoidose é uma manifestação rara 
da infeção por hepatite C, sobretudo associada a ex-
posição prévia a esquemas com interferão. Apesar de es-
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tarmos numa nova era do tratamento da hepatite C, há 
ainda poucos dados em relação ao papel dos antivíricos 
de ação direta no tratamento das complicações extra-
hepáticas da doença, especialmente as raras, como a 
neurossarcoidose. Sumário: Apresentamos um caso raro 
de vasculite do Sistema nervoso central associada a eleva-
ção dos níveis de enzima conversora da angiotensina, 
documentação de RNA viral no líquido cefalo-raquidiano 
num doente com infeção crónica a hepatite C sem trata-
mentos prévios. O tratamento com antivíricos de ação di-
reta melhorou todas as manifestações clínicas, incluindo 
redução dos níveis de ECA e de crioglobulinas. Mensa-
gens: A neurossarcoidose é uma rara, mas bem reconhe-
cida complicação da hepatite C, mesmo em doentes sem 
exposição prévia a interferão. Os agentes de ação direta 
podem ser úteis na gestão de ambas as doenças.
© 2018 Sociedade Portuguesa de Gastrenterologia 
Publicado por S. Karger AG, Basel
Introduction
One-hundred and eighty million people worldwide 
are estimated to have chronic hepatitis C virus (HCV) 
infection. Liver manifestations vary according to the de-
gree of fibrosis, portal hypertension complications, and 
the severity of liver failure. Mixed cryoglobulinemia 
(present in up to 50% of the patients), non-Hodgkin lym-
phoma, and chronic renal disease are some of the im-
mune complex-mediated manifestations of chronic hep-
atitis C. In addition, a large spectrum of neuropsychiatric 
manifestations may be present, probably linked to vascu-
lar inflammatory changes in the central nervous system 
[1]. Sarcoidosis has been associated with chronic HCV 
infection, but mainly in patients exposed to interferon 
(IFN)-based therapies [2]. Neurosarcoidosis, which may 
be present in up to 5% of the patients with systemic sar-
coidosis, has rarely been described in HCV-infected pa-
tients, only as case reports and usually related to IFN ex-
posure [2]. In the IFN-free regimen era we are currently 
living in, treating HCV extrahepatic manifestations with 
direct antiviral agents (DAAs) is recommended [3], leav-
ing other immunosuppressive therapies, such as cortico-
steroids or rituximab, usually used in combination with 
DAAs for very severe manifestations. We describe a rare 
case of a patient diagnosed with neurosarcoidosis and 
cryoglobulinemia due to HCV infection during the inves-
tigation of neuropsychiatric manifestations, whose symp-
toms completely resolved with DAA treatment and the 
resolution of HCV infection.
Clinical Case
A 45-year-old female was referred to the internal medicine out-
patient’s clinic after the identification of several diffuse gliotic le-
sions on cerebral magnetic resonance imaging (MRI) and elevated 
levels of angiotensin-converting enzyme (ACE) in serum and ce-
rebrospinal fluid (CSF). She had a known history of clinical de-
pression and epilepsy not adequately controlled with sodium val-
proate treatment. These imaginological findings were identified 
after investigation of peripheral right facial nerve palsy, secondary 
generalized partial seizures, and finger-nose dysmetria. The initial 
computed tomography scan revealed several supratentorial hy-
podensities. Multiple foci of diffuse gliotic lesions in both brain 
hemispheres suggestive of inflammatory/vasculitic etiology were 
found on cerebral MRI (Fig. 1). Serum ACE levels were raised (436 
UI/mL) and were associated with positive rheumatoid factor (26 
UI/mL). CSF analysis showed normal glucose (74 mg/dL) and pro-
Fig. 1. Brain MRI showing multiple T2 and 
T2/FLAIR hyperintense lesions of the sub-
cortical white matter, compatible with gli-
otic lesions of vasculitic nature.
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tein (0.26 g/L) levels, mild pleocytosis (5 leucocytes/mL after cor-
rection for traumatic tap), and positive ACE levels (7 UI/mL). 
These findings were consistent with neurosarcoidosis, although 
tissue documentation of granulomatous inflammation was not 
possible. 
Diagnosis of a genotype 3a chronic HCV infection was con-
comitantly made, with a viral load of 568,000 UI/mL. Liver profile 
showed raised aspartate aminotransferase (×2) and alanine amino-
transferase (×2), normal bilirubin (0.36 mg/dL), mild thrombocy-
topenia (124,000/μL), and an international normalized ratio of 
1.02. Bridging fibrosis and moderate activity was found in the liv-
er biopsy (METAVIR score A2F3). The patient tested positive for 
type II serum cryoglobulins (25 UI/mL). By this time, a second 
lumbar puncture was performed to determine the hepatitis C viral 
load in CSF, which was positive (87 UI/mL). In addition, lower-
limb vasculitic lesions developed, interpreted in the context of the 
above-mentioned cryoglobulinemia.
Due to extrahepatic immunologic manifestations of HCV in-
fection (neurosarcoidosis and cryoglobulinemia-associated vascu-
litis), urgent treatment with an IFN-free regimen was proposed. 
The patient was started on sofosbuvir 400 mg/day, daclatasvir 90 
mg/day, and ribavirin 1,000 mg/day therapy for 24 weeks, accord-
ing to the European guidelines at that time. Her viral load at week 
4 of treatment was already negative with normalization of liver 
enzymes. Cryogobulinemia resolved, and ACE levels in serum and 
CSF decreased to 69 and 3 U/L, respectively (Fig. 2). The patient 
experienced complete resolution of the lower-limb vasculitic le-
sions and progressive improvement of the facial paresis as well as 
cerebellar symptoms. Sustained virological response was docu-
mented 12 weeks after completion of treatment. A repeated MRI 
scan (8 months after HCV infection resolution) still demonstrated 
multiple gliotic lesions but without progression when compared to 
the first examination. The patient’s epilepsy is currently controlled 
with 1,500 mg of sodium valproate/day, with no more partial or 
generalized crisis documented ever since.
Comment
HCV infection exclusion is mandatory in the suspi-
cion of sarcoidosis and/or vasculitic lesions. On the other 
hand, central nervous system involvement in HCV 
chronic infection is a heterogeneous entity. In this par-
ticular case, the presence of inflammatory lesions on MRI 
prompted the evaluation for immunologic manifesta-
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tions of the disease. The simultaneous identification of 
elevated serum and CSF ACE levels raised the suspicion 
of neurosarcoidosis.
Sarcoidosis is a known complication of chronic HCV 
infection but is mainly recognized as a complication of 
IFN-based therapies. Reports of the disease in treatment-
naïve patients exist but are scarce. The pathogenic mecha-
nism is not fully understood, but the accumulated evi-
dence suggests that this is more than a casual association 
[2]. The decrease in ACE levels after the successful treat-
ment of HCV infection with an IFN-free regimen rein-
forces a viral and/or viral-immunological related etiology, 
as secondary mixed cryoglobulinemia may also have a role 
in central nervous system lesions. Although peripheral 
nervous system and cutaneous manifestations are far more 
common with this entity, the central nervous system may 
also be involved, particularly with widespread vasculitic 
lesions, as seen in this patient [4]. Our patient developed 
peripheral nervous system (peripheral facial nerve palsy) 
and cutaneous manifestations (lower-limb vasculitis) of 
the disease, both of which regressed after successful treat-
ment of the HCV infection and cryoglobulin clearance.
Direct central nervous system involvement of HCV in-
fection may be more common than previously suspected. 
There are several studies demonstrating the presence of 
the HCV virons both in the CSF and brain tissue of pa-
tients with HCV infection [5]. Nonetheless, the link be-
tween direct central nervous system infection and the de-
velopment of vasculitic lesions of the brain is weak. Ad-
ditionally, the identification of the virus in CSF analysis 
(as with this patient) may merely reflect viral carriage 
from the periphery and not active sites of replication [6]. 
Yet, and importantly, the use of DAAs that may penetrate 
the blood-brain barrier should probably be considered 
when choosing a therapeutic scheme to treat neurological 
manifestations associated with HCV infection, although 
specific data on this subject is currently lacking.
Conclusion
We present a rare case of central nervous system vas-
culitic lesions in the context of chronic HCV infection 
associated with mixed cryoglobulinemia, elevated ACE 
levels, and documentation of viral RNA in the CSF in a 
treatment-naïve chronic HCV patient. Successful treat-
ment with an IFN-free regimen improved all clinical 
manifestations, reduced the levels of serum ACE, and re-
duced the cryoglobulin levels to undetectable. Although 
there are some alternative explanations, neurosarcoidosis 
seems to be the best one to account for the clinical picture. 
This case shows the possible beneficial effects of the new 
IFN-free regimens in the management of this condition, 
even before the consideration of other immunosuppres-
sive treatments usually used in this kind of immunologi-
cal disturbances.
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